ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 221 CHF | +1.01% |
|
-0.50% | -9.61% |
| 04-26 | Roche: positive CHMP opinion for Alecensa | CF |
| 04-26 | Roche’s Lung Cancer Drug Alecensa Backed for Approval in EU | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 195B | ||||||
| 661B | ||||||
| 566B | ||||||
| 352B | ||||||
| 332B | ||||||
| 283B |
- Stock Market
- Equities
- ROG Stock
- Charts Roche Holding AG
- Sector Chart
